Stockholm - Free Realtime Quote SEK
Isofol Medical AB (publ) (ISOFOL.ST)
As of 9:26 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
--
721.0000
12,797.0000
22,407.0000
37,119.0000
--
Operating Expense
39,453.0000
42,405.0000
180,340.0000
226,872.0000
223,614.0000
--
Operating Income
-39,453.0000
-41,684.0000
-167,543.0000
-204,465.0000
-186,495.0000
--
Net Non Operating Interest Income Expense
4,758.0000
4,573.0000
147.0000
-163.0000
-149.0000
--
Pretax Income
-34,656.0000
-37,071.0000
-159,793.0000
-200,251.0000
-188,991.0000
--
Tax Provision
--
--
--
--
1.0000
--
Net Income Common Stockholders
-34,656.0000
-37,071.0000
-159,793.0000
-200,251.0000
-188,992.0000
--
Diluted NI Available to Com Stockholders
-34,656.0000
-37,071.0000
-159,793.0000
-200,251.0000
-188,992.0000
--
Basic EPS
-0.21
-0.23
-0.99
-1.59
-3.07
--
Diluted EPS
-0.21
-0.23
-0.99
-1.59
-3.07
--
Basic Average Shares
164,513.6540
161,515.4400
161,515.4400
125,645.1640
61,468.7850
--
Diluted Average Shares
164,513.6540
161,515.4400
161,515.4400
125,645.1640
61,468.7850
--
Total Operating Income as Reported
-39,453.0000
-41,683.0000
-167,543.0000
-204,465.0000
-186,494.0000
--
Total Expenses
39,453.0000
42,405.0000
180,340.0000
226,872.0000
223,614.0000
--
Net Income from Continuing & Discontinued Operation
-34,656.0000
-37,071.0000
-159,793.0000
-200,251.0000
-188,992.0000
--
Normalized Income
-34,656.0000
-37,071.0000
-163,605.0000
-203,786.0000
-186,978.0000
--
Interest Income
4,758.0000
4,573.0000
147.0000
5.0000
4.0000
--
Interest Expense
--
--
--
168.0000
153.0000
--
Net Interest Income
4,758.0000
4,573.0000
147.0000
-163.0000
-149.0000
--
EBIT
-34,656.0000
-37,071.0000
-159,793.0000
-200,083.0000
-188,838.0000
--
EBITDA
-34,647.0000
-37,034.0000
-159,726.0000
-198,487.0000
-187,068.0000
--
Reconciled Depreciation
9.0000
37.0000
67.0000
1,596.0000
1,770.0000
--
Net Income from Continuing Operation Net Minority Interest
-34,656.0000
-37,071.0000
-159,793.0000
-200,251.0000
-188,992.0000
--
Total Unusual Items Excluding Goodwill
--
--
3,812.0000
3,535.0000
-2,014.0000
--
Total Unusual Items
--
--
3,812.0000
3,535.0000
-2,014.0000
--
Normalized EBITDA
-34,647.0000
-37,034.0000
-163,538.0000
-202,022.0000
-185,054.0000
--
12/31/2019 - 4/4/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DIABIO.ST Diagonal Bio AB (publ)
0.0384
-1.03%
ACE.ST Ascelia Pharma AB (publ)
2.2400
+1.59%
ELIC.ST Elicera Therapeutics AB (publ)
1.5550
+1.63%
KAN.ST Kancera AB (publ)
1.8940
+0.32%
CAMX.ST Camurus AB (publ)
657.00
+0.84%
ONCOZ.ST OncoZenge AB (publ)
9.87
+6.70%
FLUI.ST Fluicell AB (publ)
0.0720
-2.17%
ONCO.ST Oncopeptides AB (publ)
2.1000
+0.72%
QUIA.ST Quia Pharma AB (publ)
0.0185
-7.50%
CYXO.ST Cyxone AB (publ)
0.0400
0.00%